Bone and soft tissue sarcoma - recognition and referral
Exam Tips
- For UK exams, memorise referral thresholds: child/young person + unexplained bone pain/swelling -> very urgent X-ray within 48 hours; child/young person + enlarging unexplained lump -> very urgent ultrasound within 48 hours.
- In adults, an unexplained enlarging lump should trigger urgent ultrasound within 2 weeks; suspicious or indeterminate ultrasound with persistent concern -> suspected cancer pathway referral.
- A normal early test does not fully exclude sarcoma; persistent clinical concern requires escalation and explicit safety-netting.
- Biopsy should be done in specialist sarcoma centres because poorly sited biopsy tracts can compromise later curative surgery.
- Use age-aware pathways for 16-24 years: local services may use adult or paediatric routes, but urgency principles remain the same.
Definition
Bone and soft tissue sarcomas are rare malignant tumours of mesenchymal origin (bone, muscle, fat, fibrous tissue, vessels, or peripheral nerve sheath) that often present in primary care with non-specific musculoskeletal symptoms or an enlarging lump. In UK practice, the key clinical task is rapid recognition and time-critical referral (very urgent within 48 hours in children/young people for specific red flags, and urgent within 2 weeks in adults where indicated) to avoid diagnostic delay.
Pathophysiology
Sarcomas arise from malignant transformation of mesenchymal precursor cells, with subtype-specific molecular changes (for example, complex karyotypic instability in osteosarcoma and characteristic translocations in several soft tissue sarcomas). Bone sarcomas progressively destroy cortical/trabecular bone, provoke periosteal reaction, and can extend into surrounding soft tissues, causing pain and reduced function; soft tissue sarcomas usually grow as deep enlarging masses that may remain painless until large enough to compress adjacent structures. Haematogenous spread (especially to lung) is more typical than nodal spread for many subtypes. Imaging-pathology correlation is central: suspicious radiographic/ultrasound features trigger specialist biopsy planning to avoid contaminating future surgical planes (see typical periosteal reaction and soft-tissue mass imaging figures in standard orthopaedic oncology texts).
Risk Factors
- Previous therapeutic ionising radiation exposure
- Cancer predisposition syndromes (for example Li-Fraumeni syndrome, hereditary retinoblastoma, neurofibromatosis type 1)
- Paget disease of bone (increased risk of osteosarcoma in older adults)
- Certain chronic tissue injury/inflammation states (less common, subtype-dependent)
- Age-related patterns: bone sarcoma more frequent in children, teenagers, and young adults; soft tissue sarcoma incidence increases with age
Clinical Features
Symptoms
- Unexplained bone pain (especially persistent or progressive) in children and young people
- Loss of function of an affected limb
- Unexplained lump that is increasing in size (often painless, particularly in soft tissue sarcoma)
- Local discomfort, pressure symptoms, or late pain from mass effect
Signs
- Palpable enlarging soft tissue mass, potentially deep-seated and firm
- Unexplained bone swelling in children and young people
- Reduced range of motion or functional impairment in the affected limb
- Imaging red flags: destructive bone lesion/periosteal reaction on X-ray, or suspicious/indeterminate ultrasound mass
Investigations
Management
Lifestyle Modifications
- Give clear safety-netting: advise prompt re-attendance for ongoing growth of a lump, persistent bone pain, or worsening function even if initial tests are non-diagnostic
- Provide written information and emphasise attendance at urgent cancer appointments
- Coordinate fast referral logistics: referral sent within 1 working day once decision made, with urgency clearly documented
- Consider early specialist discussion when symptoms are atypical but concern remains high
Pharmacological Treatment
Analgesia while awaiting urgent investigation/referral
- Paracetamol oral 1 g every 4-6 hours when required (maximum 4 g daily) in adults
- Ibuprofen oral 200-400 mg three times daily with food (adult OTC max 1.2 g/day; higher only on prescription)
- Codeine phosphate oral 30-60 mg every 4 hours when required (maximum 240 mg daily) for short-term rescue pain control in adults
Analgesia should not delay imaging/referral. Avoid or use caution with NSAIDs in peptic ulcer disease, severe heart failure, significant renal impairment, NSAID hypersensitivity/asthma exacerbated by NSAIDs, anticoagulant use, and late pregnancy. Avoid codeine in children under 12 years and after tonsil/adenoid surgery for OSA; counsel about constipation, sedation, dependence risk, and driving impairment. Check total paracetamol dose across combination products to prevent hepatotoxicity.
Definitive systemic therapy (specialist sarcoma MDT)
- Doxorubicin 75 mg/m^2 IV every 21 days (common first-line regimen component for advanced soft tissue sarcoma)
- Ifosfamide 9-10 g/m^2 per cycle IV in divided doses with mesna uroprotection
- Methotrexate (high-dose), doxorubicin, and cisplatin combinations for osteosarcoma in specialist protocols
Given only in specialist oncology settings. Key safety issues: anthracycline cardiotoxicity (baseline/interval cardiac assessment), ifosfamide nephrotoxicity and encephalopathy risk, severe myelosuppression/infection risk, and methotrexate interactions/toxicity requiring protocolised monitoring and folinic acid rescue where indicated.
Surgical / Interventional
- Urgent referral to a sarcoma multidisciplinary team for diagnostic pathway and treatment planning
- Image-guided core biopsy in specialist centre before definitive resection
- Limb-sparing wide local excision where feasible for localised disease
- Amputation only when necessary for local control or function/survival benefit
- Metastasectomy or radiotherapy in selected cases, based on site, stage, and histology
Complications
- Metastatic spread, especially to lungs
- Pathological fracture (bone sarcoma)
- Local neurovascular compromise from tumour growth
- Local recurrence after treatment
- Treatment-related complications (cardiotoxicity, infertility risk, infection due to chemotherapy-induced neutropenia)
Prognosis
In UK population data, 5-year survival is over 65% for bone sarcoma and around 70% for soft tissue sarcoma, but outcome varies markedly by histological subtype, tumour size/depth/site, grade, metastatic status at diagnosis, and speed of specialist management.